Please Wait

Applying Filters...

Technical details about Mirvetuximab Soravtansine, learn more about the structure, uses, toxicity, action, side effects and more

Mirvetuximab Soravtansine

Synopsis, Chemistry

DEVELOPMENTS

16 Drug(s) in Development

16 Drug(s) in Development

DOSSIERs // Finished Dosage Forms

1 Dossiers, 1 FDA Orange Book

DIGITAL CONTENT

29 News

29 News

1. Also known as: Humov 19, Unii-98de7vn88d, Imgn853, Imgn 853, Mirvetuximab soravtansine [usan], Mirvetuximab-soravtansine

Molecular Formula

C₄₂H₆₁ClN₄O₁₄S₃

Molecular Weight

977.6 g/mol

InChI Key

ZOHXWSHGANNQGO-DSIKUUPMSA-N

Mirvetuximab Soravtansine is an immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid

2.1.2 InChI

InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1

2.1.3 InChI Key

ZOHXWSHGANNQGO-DSIKUUPMSA-N

2.1.4 Canonical SMILES

CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)C)OC)(NC(=O)O2)O

2.1.5 Isomeric SMILES

C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\C)OC)(NC(=O)O2)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Imgn-853

2. Imgn853

2.2.2 Depositor-Supplied Synonyms

1. Humov 19

2. Unii-98de7vn88d

3. Imgn853

4. Imgn 853

5. Mirvetuximab Soravtansine [usan]

6. Mirvetuximab-soravtansine

7. 98de7vn88d

8. Imgn-853

9. Schembl16447449

10. 1453084-37-1

11. Immunoglobulin G1, Anti-(human Folate Receptor Alpha) (human-mus Musculus Monoclonal M9346a Heavy Chain), Disulfide With Human-mus Musculus Monoclonal M9346a Light Chain, Dimer, Tetraamide With N2'-(4-((3-carboxy-3-sulfopropyl)dithio)-4-methyl-1-oxopentyl)-n2'-deacetylmaytansine

12. Q27272114

2.3 Create Date

2015-07-11

3 Chemical and Physical Properties

Molecular Formula	C₄₂H₆₁ClN₄O₁₄S₃
Molecular Weight	977.6 g/mol
XLogP3	1.8
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	16
Exact Mass	976.3034938 g/mol
Monoisotopic Mass	976.3034938 g/mol
Topological Polar Surface Area	313 Å²
Heavy Atom Count	64
Formal Charge	0
Complexity	1890
Isotope Atom Count	0
Defined Atom Stereocenter Count	8
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	2
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of fallopian tube cancer , Treatment of ovarian carcinoma, Treatment of peritoneal carcinoma

POST ENQUIRY